maobin2

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC50 values of 0.51 μM and 7.00 μM, respectively. It attenuates H2O2-induced cellular damage due to its strong ROS scavenging properties.

MAO-B-IN-28 (compound 10e) is a potent hMAO-B inhibitor with an IC50 value of 1.9±0.5 nM, potentially serving as a candidate molecule for neurodegenerative disease research.

BChE/MAO-B-IN-2 is a dual inhibitor with excellent blood-brain barrier permeability, targeting BChE (IC50 = 0.05 μM, Ki = 0.01 μM) and MAO-B (IC50 = 0.45 μM, Ki = 0.08 μM). It exhibits antioxidant properties, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. BChE/MAO-B-IN-2 is applicable in Alzheimer's disease (AD) research.

hMAO-B-IN-2 (compound 6j) is an orally active, potent, selective, BBB-penetrating, and competitively reversible inhibitor of hMAO-B (IC50 = 4 nM) used in Alzheimer's disease research. hMAO-B-IN-2 exhibits good neuroprotective effects and low toxicity in SH-SY5Y cells [1].

Dual AChE-MAO B-IN-2 is a potent dual inhibitor of AChE (IC50: 0.12 μM) and MAO B (IC50: 0.01 μM) with potential for Alzheimer's disease studies.

AChE/BChE/MAO-B-IN-2 is a potent inhibitor of the enzymes AChE, BChE, and MAO-B, with IC50 values of 48.2 nM, 83.9 nM, and 31.2 nM, respectively. It also exhibits significant antioxidant activity and is applicable in Parkinson's disease research.

MAO-B-IN-20 (Compound C14), a potent MAO-B inhibitor with an IC50 of 0.037 μM, demonstrates excellent metabolic stability and brain-blood barrier permeability, holding potential for Parkinson's disease research [1].

MAO-B-IN-21 is an MAO-B inhibitor characterized by superior antioxidant and anti-Aβ aggregation activities, metal-ion chelating capabilities, and mitigation of neuroinflammation (NO, TNF-α). It demonstrates neuroprotective effects with notable BBB permeability and, in an Aβ1-42 induced Alzheimer's disease mouse model, significantly enhances memory and cognitive functions [1].

AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent inhibitor of AChE, BuChE, and hu MAO-B, with respective IC50 values of 5.3 μM, 12.4 μM, and 1.9±0.08 μM, indicating good in vitro blood-brain barrier (BBB) permeability. It effectively reduces excessive AChE and BuChE levels associated with Alzheimer's disease (AD) and holds potential for anti-Alzheimer's research [1].

MAO-B-IN-23, also known as Compound 11f, is a reversible and competitive monoamine oxidase B (MAO-B) inhibitor with an IC50 value of 1.44 μM and a Ki of 0.51 μM [1].

MAO-B-IN-24 (compound 11h) is a selective, reversible, competitive inhibitor of MAO-B with an IC50 value of 1.60 μM and an IC50 of 22.42 μM for MAO-A. At 10 μM concentration, it reduces AChE and BChE activities to 54.58% and 88.43%, respectively [1].

MAO-B-IN-22 (compound 6h) is a potent MAO-B inhibitor with an IC50 value of 0.014 μM, exhibiting significant antioxidant activity, effective metal-chelating properties, adequate BBB permeability, and notable neuroprotective effects [1].

MAO-B-IN-25 (compound 92) is a selective monoamine oxidase B (MAO-B) inhibitor with half-maximal inhibitory concentrations (IC50) of 240 nM for MAO-B and 0.5 nM for MAO-A [1].

MAO-B-IN-27 (Compound 12c), a monoamine oxidase B (MAO-B) inhibitor, exhibits a potent and selective inhibitory effect on hMAO-B with an IC50 value of 8.9 nM, and is utilized in Parkinson's disease (PD) research [1].

MAO-B-IN-26 (Compound IC9) is a dual MAO-B and acetylcholinesterase inhibitor that protects SH-SY5Y cells from Aβ-induced toxicity, including morphological alterations, reactive oxygen species (ROS) production, and membrane damage, while preventing Aβ-triggered autophagy and apoptosis, thus showing potential as a neuroprotective agent in Alzheimer's disease [1].

MAO-B-IN-29 (compound 9a) acts as an inhibitor of MAO-B activity [1].